國家衛生研究院 NHRI:Item 3990099045/3613
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 855167      在线人数 : 1004
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/3613


    题名: Development of multi-phase emulsions based on bioresorbable polymers and oily adjuvant
    作者: Huang, MH;Huang, CY;Lien, SP;Siao, SY;Chou, AH;Chen, HW;Liu, SJ;Leng, CH;Chong, P
    贡献者: Vaccine Research and Development Center
    摘要: Purpose: To enhance the water affinity of W/O emulsion-adjuvanted vaccines, we used three bioresorbable polymers named PEG-b-PLA, PEG-b-PCL, and PEG-b-PLACL as hydrophilic emulsifier to stabilize the interfaces between the oily Montanide ISA 51 adjuvant and the antigen media. Methods: Polymers were synthesized by ring-opening polymerization of lactide and/or ε-caprolactone in the presence of monomethoxy PEG. 1H NMR and GPC data showed that obtained polymers consisted of 70 wt.% hydrophilic PEG block and 30 wt.% lipophilic PLA, PCL, PLACL block with molecular weights of 7,000. Results: The polymer-stabilized ISA51 emulsions have high affinity to water, such that the stock of antigen-encapsulating emulsion could be re-dispersed into PBS before injection, thus yielding stable and injectable W/O/W emulsion nanoparticles. Immunogenicity studies showed that PEG-b-PLACL/ISA51/PBS-formulated ovalbumin with only 5% of ISA51 oily adjuvant could induce the same level of antibody titers as those induced by PBS/ISA51-formulated ovalbumin. Conclusions: The novel multi-phase emulsions increase fluidity and conceptually diminish local reactions with respect to the W/O type vaccines produced from the same oil. These features are of great interest for applications in candidate vaccine delivery, especially for further optimization of alternative immunization routes, such as intramuscular, transdermal or mucosal administration.
    日期: 2009-08
    關聯: Pharmaceutical Research. 2009 Aug;26(8):1856-1862.
    Link to: http://dx.doi.org/10.1007/s11095-009-9898-y
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0724-8741&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000267685800007
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=67650032608
    显示于类别:[莊再成] 期刊論文
    [冷治湘] 期刊論文
    [劉士任] 期刊論文
    [陳信偉] 期刊論文
    [黃明熙] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    SCP67650032608.pdf267KbAdobe PDF742检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈